SCHEMBL20101624

SCHEMBL20101624

C/C=C\C=C/CC(C)(C)C

nearest known ligand 0.32

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 5/20 0.32
CNR2 P34972 5/20 0.32
TRPA1 O75762 1/20 0.32
TRPV1 Q8NER1 1/20 0.32
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27524666 1.00 CNR1 (0.32) CNR1CNR2TRPA1TRPV1ALDH1A1
SCHEMBL2000208 0.78
SCHEMBL21523586 0.78
SCHEMBL2000209 0.78
SCHEMBL22806505 0.74
SCHEMBL13823332 0.74
SCHEMBL22806504 0.74
SCHEMBL10898975 0.73
SCHEMBL8506813 0.72 ALDH1A1 (0.33) ALDH1A1
SCHEMBL26766345 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180118749-A1 P2X7 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180118749-A1 P2X7 MODULATORS P2RX7, P2RX3, P2RX1 CNR1 90/4885CNR2 72/4885TRPA1 65/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.